DuPont de Nemours, Inc. DD has launched AmberChrom SIL silica gel, a new reverse-phase silica-based chromatography media designed to support the purification and manufacturing of peptide therapeutics, including glucagon-like peptide-1 (GLP-1) receptor agonists. The launch expands DuPont’s bioprocessing purification portfolio and strengthens its suitability for high-purity polishing.
Growing demand for peptide therapeutics for the treatment of diabetes, obesity and other chronic conditions is increasing the need for efficient purification technologies at a larger scale. AmberChrom SIL silica gel is designed to help biopharmaceutical manufacturers meet stringent purity requirements while maintaining high yields.
Available in C8 and C18 chemistries, the new product offers high resolution, stability and scalability for demanding peptide separations. It can be used during multiple stages of purification to address diverse impurity profiles and specific process requirements.
DuPont’s latest launch can also be integrated with its existing chromatography technologies, including AmberChrom XT, AmberChrom TQ1 and CG resins. Combining silica-based and polymeric chromatography technologies with a single purification workflow enables manufacturers to optimize purity, yield and recovery across multiple stages.
The launch reinforces DuPont’s focus on expanding its solutions to address evolving needs by offering process development and manufacturing scale-up to optimize purification workflows and achieve purity targets.
Shares of DD have lost 44.4% over the past year against the 1.2% rise of its industry.
Image Source: Zacks Investment Research
DD’s Zacks Rank & Key Picks
DDcurrently carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the Basic Materials space are Reliance, Inc. RS, Cabot Corporation CBT and Avient Corporation AVNT.
RS currently sports a Zacks Rank #1 (Strong Buy), while CBT and AVNT carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here
The Zacks Consensus Estimate for RS’ 2026 earnings is pegged at $23.70 per share, indicating a 66.2% year-over-year surge. RSshares have gained 50.8% over the past year.
The Zacks Consensus Estimate for CBT’s current fiscal-year earnings is pinned at $6.35 per share. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters, with an average surprise of 4.56%. CBTshares have gained 4.2% over the past year.
The Zacks Consensus Estimate for AVNT’s 2026 earnings is pegged at $3.2 per share, indicating a year-over-year rise of 13.48%. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DuPont de Nemours, Inc. (DD): Free Stock Analysis Report
Reliance, Inc. (RS): Free Stock Analysis Report
Cabot Corporation (CBT): Free Stock Analysis Report
Avient Corporation (AVNT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).